Cerba HealthCare announced on September 7 that it has acquired Cirion BioPharma Research, a contract research organization (CRO) in Laval, Quebec.
Cirion BioPharma Research is a Canadian contract research laboratory providing global central laboratory services for clinical studies and research and development services.
Cerba Healthcare is a leader in clinical pathology specializing in local clinical pathology, specialized clinical pathology and central lab testing for clinical trials. Its shareholders include Partners Group and the Public Sector Pension Investment Boards.
Cirion will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of laboratories in the Americas, Europe, Africa and Asia-Pacific. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 27th CRO acquisition of 2023. This also marks Cerba’s first healthcare transaction of the year. In 2022, the company acquired Viroclinics-DDL, a specialty CRO in Rotterdam, Rijswijk and Schaijk, Netherlands.
